161 related articles for article (PubMed ID: 36210625)
1. STAT3 is Activated by CTGF-mediated Tumor-stroma Cross Talk to Promote HCC Progression.
Makino Y; Hikita H; Kato S; Sugiyama M; Shigekawa M; Sakamoto T; Sasaki Y; Murai K; Sakane S; Kodama T; Sakamori R; Kobayashi S; Eguchi H; Takemura N; Kokudo N; Yokoi H; Mukoyama M; Tatsumi T; Takehara T
Cell Mol Gastroenterol Hepatol; 2023; 15(1):99-119. PubMed ID: 36210625
[TBL] [Abstract][Full Text] [Related]
2. CTGF Mediates Tumor-Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression.
Makino Y; Hikita H; Kodama T; Shigekawa M; Yamada R; Sakamori R; Eguchi H; Morii E; Yokoi H; Mukoyama M; Hiroshi S; Tatsumi T; Takehara T
Cancer Res; 2018 Sep; 78(17):4902-4914. PubMed ID: 29967264
[TBL] [Abstract][Full Text] [Related]
3. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
5. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
6. Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model.
Thiem S; Eissmann MF; Elzer J; Jonas A; Putoczki TL; Poh A; Nguyen P; Preaudet A; Flanagan D; Vincan E; Waring P; Buchert M; Jarnicki A; Ernst M
Cancer Res; 2016 Apr; 76(8):2277-87. PubMed ID: 26837764
[TBL] [Abstract][Full Text] [Related]
7. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
8. IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment.
Zheng X; Xu M; Yao B; Wang C; Jia Y; Liu Q
Cell Signal; 2016 Sep; 28(9):1314-1324. PubMed ID: 27297362
[TBL] [Abstract][Full Text] [Related]
9. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
[TBL] [Abstract][Full Text] [Related]
10. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
[TBL] [Abstract][Full Text] [Related]
11. Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors.
Akahoshi K; Tanaka S; Mogushi K; Shimada S; Matsumura S; Akiyama Y; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
J Gastroenterol; 2016 Sep; 51(9):910-22. PubMed ID: 26739296
[TBL] [Abstract][Full Text] [Related]
12. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
[TBL] [Abstract][Full Text] [Related]
13. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
14. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
15. Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling.
Luo YD; Liu XY; Fang L; Yu HQ; Zhang YJ; Chen M; Zhang LD; Xie CM
Theranostics; 2022; 12(18):7903-7919. PubMed ID: 36451866
[No Abstract] [Full Text] [Related]
16. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
17. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.
Won C; Kim BH; Yi EH; Choi KJ; Kim EK; Jeong JM; Lee JH; Jang JJ; Yoon JH; Jeong WI; Park IC; Kim TW; Bae SS; Factor VM; Ma S; Thorgeirsson SS; Lee YH; Ye SK
Hepatology; 2015 Oct; 62(4):1160-73. PubMed ID: 26154152
[TBL] [Abstract][Full Text] [Related]
18. Molecular dissection of gp130-dependent pathways in hepatocytes during liver regeneration.
Dierssen U; Beraza N; Lutz HH; Liedtke C; Ernst M; Wasmuth HE; Trautwein C
J Biol Chem; 2008 Apr; 283(15):9886-95. PubMed ID: 18216023
[TBL] [Abstract][Full Text] [Related]
19. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma.
Yin Z; Ma T; Lin Y; Lu X; Zhang C; Chen S; Jian Z
J Cell Biochem; 2018 Nov; 119(11):9419-9432. PubMed ID: 30015355
[TBL] [Abstract][Full Text] [Related]
20. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.
Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J
Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
